MedTrace Logo

Chamomile Therapy for Generalized Anxiety

NCT00645983 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2009-12-02

No results posted yet for this study

Summary

This study will determine the effectiveness of chamomile extract for treating generalized anxiety disorder.

Study hypotheses: 1)Chamomile extract will have a superior anti-anxiety effect compared to placebo. 2)Chamomile will have a comparable safety profile to that of placebo.

Conditions

  • Generalized Anxiety Disorder

Interventions

DIETARY_SUPPLEMENT

Chamomile Extract

220 mg - 1100 mg daily

OTHER

Placebo

1 to 5 capsules daily

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • Office of Dietary Supplements (ODS)

    collaborator NIH

  • University of Pennsylvania

    lead OTHER

Principal Investigators

  • Jay D. Amsterdam, M.D. · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00645983 on ClinicalTrials.gov